BACKGROUND: Experimental data have provided evidence that progenitor cells of bone
marrow (BM) origin may play a role in the fibrogenic process of the lung. OBJECTIVE: To …

Abstract Objectives Mesenchymal stem cells (MSCs) have shown great potential in treating
autoimmune diseases (ADs). Unlike the traditional immunosuppressants, which …

Mesenchymal stem cells (MSCs) are emerging as a therapeutic modality in various
inflammatory disease states. A number of ongoing randomized Phase I/II clinical trials are …

The immune system is receiving increasing attention for interstitial lung diseases, as
knowledge on its role in fibrosis development and response to therapies is expanding …

Lung fibrosis is a severe condition resulting from several interstial lung diseases (ILD) with
different etiologies. Current therapy of ILD, especially those associated with connective …

Mesenchymal stem cells (MSCs) have been exploited as cellular vectors to treat a wide
array of diseases but the mechanisms responsible for their therapeutic effect remain …

COPD is characterised by tissue destruction and inflammation. Given the lack of curative
treatments and the progressive nature of the disease, new treatments for COPD are highly …

Backgroud There is an unmet need for the development of new biomarkers for idiopathic
inflammatory myopathy-associated interstitial lung disease (IIM-ILD). Methods Peripheral …

Background. Immunosuppressants such as cyclophosphamide (CTX) have been employed
to treat a wide array of autoimmune diseases. The most unfavourable side effects of these …

Mesenchymal stromal/stem cells are multipotent adult cells that can be extracted from
numerous tissues, including the lungs. Lung-resident MSCs (LR-MSCs) are localized to …